



Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges

Carmine Zoccali ¹, Alberto Ortiz ², Inga Arune Blumbyte³, Sarina Rudolf⁴, Annette G. Beck-Sickinger ⁴, Jolanta Malyszko⁵, Goce Spasovski⁶, Sol Carriazo ², Davide Viggiano⁷, Justina Kurganaite³, Vaiva Sarkeviciene³, Daiva Rastenyte⁸, Andreja Figurek⁹, Merita Rroji¹⁰, Christopher Mayer¹¹, Mustapha Arici¹², Gianvito Martino ¹³, Gioacchino Tedeschi¹⁴, Annette Bruchfeld ¹⁵, Belinda Spoto¹⁶, Ivan Rychlik¹⁷, Andrzej Wiećek¹⁸, Mark Okusa¹⁹, Giuseppe Remuzzi²⁰ and Francesca Mallamaci²¹; the CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target)

¹Renal Research Institute, New York, NY, USA and Associazione Ipertensione Nefrologia Trapianto Renale Reggio Cal, Italy c/o CNR-IFC, Ospedali Riuniti, Reggio Calabria, Italy, ²Faculty of Life Sciences, Institute of Biochemistry, Leipzig University, Leipzig, Germany, ³Nephrology Department, Lithuanian University of Health Sciences, Kaunas, Lithuania, ⁴Faculty of Life Sciences, Institute of Biochemistry, Leipzig University, Leipzig, Germany, ⁵Department of Nephrology, Dialysis and Internal Medicine, Warsaw Medical University, Warsaw, Poland, ⁶Department of Nephrology, University 'Sts. Cyril and Methodius,' Skopje, MK, Republic of Macedonia, ⁷Department of Translational Medical Sciences, University of Campania 'Luigi Vanvitelli,' Naples, Italy and Biogem Scarl, Ariano Irpino, Italy, ⁸Neurology Department, Lithuanian University of Health Sciences, Kaunas, Lithuania, ⁹Institute of Anatomy, University of Zurich, Zurich, Switzerland, ¹⁰Department of Nephrology, Faculty of Medicine, University of Medicine Tirana, Tirana, Albania, ¹¹Health and Bioresources, Biomedical Systems, Austrian Institute of Technology, Vienna, Austria, ¹²Department of Nephrology, Hacettepe University School of Medicine, Ankara, Turkey, ¹³Neurology Department, San Raffaele Scientific Institute and Vita-Salute University San Raffaele, Milan, Italy, ¹⁴Department of Advanced Medical and Surgical Sciences, and 3T-MRI Research Center, University of Campania 'Luigi Vanvitelli,' Naples, Italy, ¹⁵Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden and Department of Renal Medicine, CLINTEC Karolinska Institutet, Stockholm, Sweden, ¹⁶CNR-IFC, Reggio Calabria, Italy, ¹⁷Third Faculty of Medicine, Department of Medicine, Charles University and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic, ¹⁸Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia in Katowice, Katowice, Poland, ¹⁹Division of Nephrology and Center for Immunity, Inflammation, and Regenerative Medicine, University of Virginia, Charlottesville, VA, USA, ²⁰Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Clinical Research Center for Rare Diseases, Aldo e Cele Daccò Bergamo, Italy and ²¹Nephrology and Transplantation Unit, Grande Ospedale Metropolitano and CNR-IFC, Reggio Calabria, Italy

Correspondence to: Carmine Zoccali; E-mail: carmine.zoccali@tin.it

ABSTRACT

Neuropeptide Y (NPY) is a 36-amino-acid peptide member of a family also including peptide YY and pancreatic polypeptide, which are all ligands to Gi/Go coupled receptors. NPY regulates several fundamental biologic functions including appetite/satiety, sex and reproduction, learning and memory, cardiovascular and renal function and immune functions. The mesenteric circulation is a major source of NPY in the blood in man and this peptide is considered a key regulator of gut–brain cross talk. A progressive increase in circulating NPY accompanies the progression of chronic kidney disease (CKD) toward kidney failure and NPY robustly predicts

cardiovascular events in this population. Furthermore, NPY is suspected as a possible player in accelerated cognitive function decline and dementia in patients with CKD and in dialysis patients. In theory, interfering with the NPY system has relevant potential for the treatment of diverse diseases from cardiovascular and renal diseases to diseases of the central nervous system. Pharmaceutical formulations for effective drug delivery and cost, as well as the complexity of diseases potentially addressable by NPY/NPY antagonists, have been a problem until now. This in part explains the slow progress of knowledge about the NPY system in the clinical arena.




FIGURE 1: The NPY and the gut–brain axis. The graph shows the YR subtypes that mediate the effects of NPY in the CNS and at the different levels of the gut–brain axis. ↑: increase; ↓: decrease.

There is now renewed research interest in the NPY system in psychopharmacology and in pharmacology in general and new studies and a new breed of clinical trials may eventually bring the expected benefits in human health with drugs interfering with this system.

Keywords: cardiovascular, CKD, dialysis, hypertension, renin-angiotensin system

INTRODUCTION

Neuropeptide Y (NPY) is a 36-amino-acid peptide that derives from a 98-amino-acid protein (preproNPY) coded on chromosome 7p15.1. This compound is a member of a family of peptides including peptide Y (PYY) and pancreatic polypeptide (PP) that are all ligands to Gi/Go coupled receptors (Y receptors). PreproNPY generates the 69-amino-acid prohormone proNPY, which by enzymatic cleavage eventually results in the NPY molecule. The dibasic pair of amino acids, Lys38–Arg39, of the prohormone is cleaved by two convertases, PC1/3 and PC2, to generate NPY [1]. The N-terminus of NPY and PYY is readily cleaved by aminopeptidase P and dipeptidyl peptidase 4 (DP4, CD26), giving rise to the fragments NPY2-36, NPY3-36 and PYY3-36 with distinct pharmacological properties [1].

NPY regulates several fundamental biologic processes including appetite/satiety, sex and reproduction, learning and memory [2] (Figure 1). Furthermore, it has anxiolytic and antidepressant properties [2] and potently inhibits bone turnover in experimental models [3]. This peptide is highly

represented in the brain and in the central and peripheral nervous system and is ubiquitous in the cardiovascular system [4]. In the arterial system, NPY regulates vascular tone by interacting with the sympathetic system, renin-angiotensin-aldosterone system [5] and nitric oxide system [6] and key vasodilators like atrial natriuretic peptide [7] and vasorelaxant prostaglandins [8]. Notably, NPY is an established regulator of several hormone systems [9] and is involved in immune regulation [10, 11].

The mesenteric circulation is a major source of circulating NPY in man [12] and this peptide is considered as a key regulator of gut–brain crosstalk (Figure 1). This cross-talk rests on three major pathways: neural input transmitted by vagal and spinal afferent neurons, immune signals triggered by cytokines and endocrine signals by gut hormones [13]. The gut microbiota and the gastrointestinal immune system interact with each other at the level of the gastrointestinal mucosa. This interaction originates disparate signals for the brain, including cytokines, lipopolysaccharides (LPS) and peptidoglycans [14] that directly activate the central nervous system (CNS). These signals contribute to the regulation of diverse functions from digestion to immunity, metabolic homeostasis and brain function, including the emotional and cognitive dimension. Remarkably, the gut produces >20 hormones [15] and the reach of gut hormones extends from digestion, hunger and satiety and energy homeostasis to mood and emotion. The three pathways discussed above are closely interrelated. Indeed, cytokines and gastrointestinal hormones




FIGURE 2: Selectivity within the NPY family. (A) The three endogenous ligands—NPY, PYY and PP—exhibit varying degrees of affinity and specificity for four human YRs. The ligand potency at the respective receptor is reflected by the size of the sphere above. NPY and PYY bind with relatively high affinity to Y1R, Y2R and Y5R. In contrast, PP binds predominantly to Y4R and with lower affinity to Y5R. (B) Phylogeny of the human YRs resulting in three receptor subfamilies and defined preference towards a specific receptor subtype.

act on afferent vagal neurons sending messages to the brain. Deciphering how the gut–brain axis works has implications well beyond gastroenterology, extending to neurology and psychiatry.

In this review we summarize the knowledge on NPY, from target receptors to possible clinical implications of this neuropeptide in human diseases at large and in CKD in particular. In particular, we focused our attention on studies focusing on cognitive dysfunction and dementia, which is an emerging problem in the CKD population.

NPY receptors

To date, seven Y receptor (YR) subtypes (Y1R, Y2R, Y4R, Y5R, y6R–Y8R) have been described in vertebrates. The three endogenous ligands—NPY, PYY and PP—exhibit varying degrees of affinity and specificity for four human YRs (Figure 2). NPY and PYY bind with relatively high affinity to Y1R, Y2R and Y5R. In contrast, PP binds predominantly to Y4R and with lower affinity to Y5R. The phylogeny of the human YRs results in three receptor subfamilies and defined preference toward a specific receptor subtype: the Y1R subfamily (Y1R, Y4R, y6R and Y8R), the Y2R subfamily (Y2R and Y7R) and the single-gene Y5R subfamily [16] (Figure 3). The Y1R subfamily is equally distant from the Y2R and Y5R subfamilies [17], which are also equally distant to one another. The original chromosome containing the receptor genes duplicated twice in vertebrates. Thus the genes coding for Y1R, Y2R and Y5R arose by a local duplication of a common receptor ancestor and are present on the same chromosome in humans. Subsequently a second duplication led to the Y1R-like genes Y4R and y6R [18]. Only five receptor subtypes are present in mammals (Y1R, Y2R, Y4R, Y5R and y6R). While Y1R, Y2R, Y4R and Y5R are functional in all mammals, the y6R is non-functional in several mammals and in man and Y7R and Y8R were lost in the lineage leading to mammals [16]. The receptor that was originally identified as Y3R, based on pharmacological studies, has now been characterized as CXC chemokine receptor type 4 and is therefore included in the chemokine receptor family [19]. Compared with other G protein-coupled receptor families, the human YRs exhibit relatively low levels of sequence identity. Y1R shares its closest amino acid identity with Y4R (42%) and the non-active form y6R (51%) (Figure 3) but lower homology




FIGURE 3: NPY receptors. Y1R, Y2R, Y4R and Y5R are the four active receptors in mammals. y6R is functionally inactive and Y7R and Y8R got lost in the lineage leading to mammals.

to Y2R (31%) and Y5R (35%). In addition to distinct amino acid sequences, each of the YRs is characterized by a unique pharmacological profile and distinct tissue localization.

Y1R. The Y1R subtype is predominantly expressed in the CNS and brain, including regions such as the cerebral cortex, hypothalamus, thalamus and amygdala [20] and in a variety of tissues like heart, kidney, lung, colon, muscle cells, gastrointestinal tract and blood vessels [1]. The most important Y1R-mediated effects of NPY are vasoconstriction, anxiolysis [1] and the stimulation of feeding, together with Y5R. Y1R displays a highly conserved structure with overall identities of 94% to its orthologs and the human gene has been localized to chromosome 4q31.3–32 [21, 22]. Y1R exhibits almost equally high affinity for NPY and PYY but very low affinity for PP (Figure 2). All N-terminally truncated versions of NPY, such as NPY2-36, NPY3-36 and NPY13-36, show intermediate or no affinity for Y1R [22].

Y2R. Y2R is predominantly expressed in the CNS, including regions such as the brain cortex and hippocampus [23], but is also located in the intestine and blood vessels. The presynaptically expressed receptor suppresses neurotransmitter release [24]. The human Y2R gene is localized on chromosome 4q31–32 in proximity to the Y1R and Y5R gene clusters [25]. Y2R

shares a very low degree of identity with Y1R (31%) but is highly conserved in mammals, showing 90% identity. Like Y1R, the receptor has high affinity for NPY and PYY, but not for PP (Figure 2). Y2R is pharmacologically characterized by its ability to retain high affinity for N-terminally truncated peptide fragments, for instance, NPY3-36, NPY13-36, PYY3-36 and PYY13-36 [1]. This receptor modulates fat mass and fundamental metabolic functions, including the control of serum glucose, insulin and serum cholesterol.

Y4R. Y4R is predominantly expressed in peripheral tissues such as heart, intestine, colon, pancreas, testis, prostate, lung and skeletal muscle [26] and, to a weak extent, in the hypothalamus, amygdala and thalamus [27]. Y4R activation inhibits pancreatic secretion and gall bladder contraction [28]. Y4R has one of the least conserved sequences of the NPY hormone family, making it the fastest evolving receptor subtype. The receptor is most closely related to Y1R (42%) and the truncated y6R (38%), as they evolved from a common ancestral gene [1]. The conservation between species is much less (75%) than that exhibited by Y1R and Y2R. In contrast to Y1R and Y2R, this subtype exhibits a high affinity for PP and PYY, particularly for PP [29].

Y5R. The Y5R gene generates two splice variants that differ in the N-terminal 10-amino-acid extension. The long isoform consists of 455 amino acids and the short isoform of 445 amino acids, which show no differences in their pharmacological profile [30]. Y5R is mainly expressed in the hippocampus and hypothalamus, where it regulates food intake, while it is rarely observed in peripheral tissues. However, Y5R messenger RNA has also been detected in the pancreas, gastrointestinal tract, muscle cells and cardiomyocytes [31]. The Y1R and Y5R genes are transcribed in opposite directions from a common promoter region on chromosome 4q31.3–32 [31]. Y5R is almost always localized in neurons that also express Y1R and Y5R exhibits very low identity to other YRs, with the highest identity (35%) to the Y1R. Some unusual features are the extended intracellular loop 3 and short C-terminus. The protein is very well conserved in mammals, with 90% overall identity. The Y5R pharmacological profile shares many features with that of Y1R. Y5R exhibits almost equally high affinity for NPY, PYY and PP. N-terminally truncated NPY, NPY13–36, shows intermediate affinity for Y5R and the receptor has substantial affinity for Y2R-specific agonists such as NPY2-36 and NPY3-36 [2]. The first Y5R-selective agonist was [Ala31,Aib32]-NPY, where residues 31 and 32 of NPY were substituted by the dipeptide Ala- α -aminoisobutyric acid in order to induce a more flexible 310-helical-turn structure in the C-terminal peptide region [32]. Thus Y5R selectivity is related to the destabilization of the α -helical conformation at the C-terminal tetrapeptide, as shown for both Y5R-selective analogs [Ala31, Aib32]-NPY and [Ala31, Pro32]-NPY [33]. The variants [D-Trp32]-NPY and [D-Trp34]-NPY show particularly improved affinity for Y5R, with significantly reduced potency at Y1R, Y2R, Y4R and y6R [34]. *In vivo* investigation demonstrated that the orexigenic potency of [D-Trp34]-NPY exceeded that of [D-Trp32]-NPY [106].

Extensive knowledge on NPY and NPY receptors in animal models has been gathered over the last 30 years. However, apart from a dose-finding study testing NPY administered intranasally in post-traumatic depression [35], until now no clinical trial has been performed. The issue of clinical trials targeting YRs is discussed in the conclusive part of this review.

NPY, the cardiovascular system and the kidney

Along with its representation in the autonomic system and co-release with norepinephrine, circulating NPY increases in response to physical exercise and orthostatism and in disease states characterized by high sympathetic tone, like heart failure and cardiac ischaemia [4]. Sympathetic nerve activity is augmented early on in CKD [36] and increases progressively with declining renal function [37], which goes along with the severity of hypertension and left ventricular hypertrophy (LVH) [38, 39] in this condition. Similarly, a study based on two CKD cohorts documented a gradual increase in circulating NPY at progressively more severe degrees of renal dysfunction [40]. Like norepinephrine, this peptide exerts pro-atherogenic effects because it promotes vascular smooth muscle proliferation, stimulates monocyte migration and activation, activates platelets and stimulates angiogenesis [41]. In injured rat carotid arteries, local delivery of NPY intensifies neointimal hyperplasia and this alteration improves with Y1R antagonism [42, 43]. Independent of hypertension, in CKD patients carotid intima thickness is strongly associated ($R^2 = 0.71$) with the gene expression levels of NPY [44]. However, the molecular NPY fragment 3-36 has favorable protective effects for the cardiovascular system because it stimulates Y2R-mediated neo-angiogenesis in experimental ischaemia and has an antifibrotic effect at the myocardial level [45].

Observations in patients with kidney failure (Stage G5 CKD) associated circulating NPY levels with LVH [46] and incident cardiovascular complications [47] and the link between NPY and incident cardiovascular events was more recently confirmed in pre-dialysis CKD patients [48]. The direct link between NPY and left ventricular mass in kidney failure goes along with experimental observations showing that long-term subcutaneous infusion of NPY induces cardiac hypertrophy and dysfunction in rats [49], an effect mediated via calcineurin signaling [50] and the microRNA-216b/FoxO4 signaling pathway [51]. On the other hand, other experimental data indicate that NPY co-released with norepinephrine mitigates the hypertrophic response of adult ventricular cardiomyocytes to norepinephrine [52]. Overall, the direct hypertrophic effect of NPY probably prevails in the mitigation of norepinephrine-induced LVH by the same peptide. NPY is a compound characterized by slow release and persistent actions under physiological conditions. Chronically increased NPY levels in the rat cause a doubling in cardiomyocyte mass [49]. Sitagliptin, a dipeptidyl-peptidase 4 inhibitor, which increases NPY levels and potentiates the vasoconstrictive response to NPY in healthy humans [5], augments the risk for heart failure in diabetic patients on dialysis [53], a population where LVH is robustly associated with NPY levels [46, 47].

Renal disease progression is a multifactorial problem and sympathetic overactivity is a well-documented risk factor for adverse renal outcomes [36, 54, 55]. Together with hypertension, proteinuria is considered as the most important modifiable risk factor for CKD progression. NPY levels correlated with proteinuria and glomerular filtration rate and predicted a faster progression rate toward kidney failure in the two-cohort study in CKD patients discussed above [40]. The rs16139 polymorphism in the NPY gene associates with proteinuria [41] and increased susceptibility to nephropathy in type 1 diabetic patients [42], suggesting that the link between NPY and proteinuria is causal in nature, at least in type 1 diabetic patients. NPY levels decrease after renal denervation [56], and future studies applying this technique in patients with treatment-resistant hypertension may explore whether a reduction in NPY is key to renoprotection in these patients. As alluded to before, NPY is an immunomodulatory factor [11]. Inflammation is a fundamental risk factor for the progression of CKD toward kidney failure [57] and future studies should test whether NPY contributes to CKD progression by interfering with the inflammatory pathway. NPY is downregulated in insulin-resistant versus insulin-sensitive mouse podocytes and in human glomeruli of patients with diabetic kidney disease [58]. This contrasts with the increased NPY levels that are commonly observed in CKD patients. However, NPY knockout mice, a model of NPY deficiency, exhibit less severe degrees of albuminuria and podocyte injury. Furthermore, NPY signaling in cultured podocytes via Y2R stimulates phosphoinositide 3-kinase, mitogen-activated protein kinase and nuclear factor of activated T-cells, which are all fundamental factors in the immune response [58].

NPY and the central and peripheral nervous system

NPY is one of the most evolutionarily conserved peptides across mammalian species [59]. It is widely represented throughout the CNS, including the cortical, limbic, hypothalamic and brainstem regions, the neocortex, the amygdala, the hippocampus and the basal ganglia, the periaqueductal grey, dorsal raphe nucleus and the A1–3 and A6 noradrenergic cell groups in the brainstem [60] (Figure 4). In the peripheral nervous system, NPY is mainly expressed in sympathetic ganglia and Y1R is densely represented in the colonic nerve plexuses.

NPY is a key neuromediator of appetite and has a relevant impact on nutrition and metabolism [61]. In rats, intracerebroventricular or intrahypothalamic administration of NPY triggers hyperphagia, body weight gain and increased adiposity, hyperinsulinemia, high leptin and high cortisol levels and reduced thermogenesis in brown adipose tissue [62, 63]. Furthermore, conditional knockdown of Y2 receptors at an adult stage prevents diet-induced obesity [64].

Importantly, NPY modulates stress-related emotions, anxiety and depression and is considered key for stress resilience. Plasma NPY concentration is increased in situations of extreme stress, like in military survival training [65]. However, when prolonged over time, stress eventually produces NPY depletion and a decline in plasma levels [65]. NPY levels are indeed reduced in patients with post-traumatic stress disorder




FIGURE 4: The figures upon which the graph is based were derived from data reported in the Human Protein Atlas. Consensus normalized expression (NX) levels of NPY for the CNS created by combining the data from the three transcriptomics datasets using internal normalization criteria (see also main text).

[66]. At least in experimental models in rodents, in most brain areas NPY levels and NPY-expressing cell counts are lower in females than in males, a phenomenon that could explain a higher susceptibility of stress-related disorders in females [67].

NPY is involved in various domains of cognitive function. The highest concentrations of NPY receptors are located in the hippocampus and high levels of NPY expression occur in brain regions important for learning and memory [68]. These effects of NPY are very diverse and complex. Indeed, this peptide can inhibit or promote memory depending on the memory type or phase (i.e. acquisition, consolidation, retention or retrieval), NPY dose applied, receptor type and brain region [69]. NPY enhances retention, a critical memory phase, when infused into the rostral hippocampus and septum, but inhibits this process when infused into the amygdala and caudal hippocampus and is ineffective when infused into the thalamus, caudate or cortical regions above the rostral hippocampus and septum [70]. Furthermore, NPY is more effective in enhancing memory consolidation, retention and retrieval than memory acquisition. Recently studies on social and non-social cognition have been performed in mice [71]. Social memory is the ability of mice to discriminate between a previously encountered mouse and a novel mouse (social discrimination test) while non-social memory is the ability to discriminate between a previously encountered and a novel object (object discrimination test). Intracerebroventricular infusion of NPY prolonged retention of non-social memory, but not social memory, and the Y1R antagonist BIBO3304 trifluoroacetate blocked the effect of NPY [71].

The effects of NPY on cognitive processes have been little investigated in man. Assessing the role of NPY in these processes is fundamental in the clinical perspective of dementia. Studies in the 1990s [72] observed subnormal NPY levels in the cerebrospinal fluid of patients with dementia of Alzheimer's type, a condition characterized by neuronal degeneration of temporo parietal and temporo limbic structures. This

Table 1. Genetic variants of NPY and its receptors and their associated phenotypes

Gene	Variants, <i>N</i>	Variants with a frequency > 1:100 and their type, <i>n</i>	Variants reported in ClinVar and their frequency in the population	NPY levels and neurological phenotype	Cardiovascular phenotype
NPY	198	7 (3 synonymous variants, 1 5' UTR variant, rs16139 (3%) 2 intron variants and 1 missense variant)		↓ plasma NPY ↑ alcohol intake	↑ serum LDL ↑ carotid intima–edia thickness
NPY1R	313	2 (5' UTR variants)	rs5578 (0.5%)	n.a.	n.a.
NPY2R	347	2 (synonymous variants)	rs141746382 (0.04%); rs200831948 (<0.001%); rs142187929 (0.03%)	n.a.	n.a.
NPY5R	359	2 (5' UTR variants)	rs188410293 (0.03%); rs77419821 (<0.001%)	n.a.	n.a.

Further details on other gene variants associated with CNS and cardiovascular diseases are shown in Supplementary data, Table S1.
n.a.: not available.

phenomenon was specific to Alzheimer's dementia because no such alteration was registered in patients with frontotemporal degeneration of the non-Alzheimer's type. Of note, cerebrospinal fluid levels of NPY correlated with clinical symptoms such as restlessness, anxiety, irritability and depression [73]. In contrast, other studies failed to confirm these observations [74]. Data in experimental models have coherently shown that NPY is a neuroprotective peptide because it facilitates neurogenesis, has trophic effects on the nervous system and inhibits neuroinflammation [74]. However, no clinical trial until now has tested the hypothesis that these effects may translate into real clinical benefits in dementia. A randomized dose-ranging study of NPY in 26 patients with post-traumatic stress disorder showed that higher doses of NPY administered by a nasal route are associated with a greater treatment effect, favoring NPY over placebo on the Beck Anxiety Inventory score [35]. In 2019 a clinical trial was registered for testing intranasal NPY in level 2 trauma patients with post-traumatic stress disorder [75], but apparently recruitment of patients has yet to be started. About a quarter of hemodialysis patients in New Orleans developed post-traumatic stress disorder after hurricane Katrina [76]. Several other examples of exposure of the hemodialysis population to environmental disasters exist [77]. These disasters provide an interesting opportunity for studying the association between NPY levels and this disorder. Indeed, NPY in hemodialysis patients is about 6 times higher than in healthy individuals [46, 47] and, at least in theory, accumulation of NPY may protect hemodialysis patients from the same disorder. Cognitive dysfunction is common in the CKD population, particularly so among end-stage kidney disease patients [78]. At present we have no understanding of whether increased NPY levels in CKD and hemodialysis patients are protective, neutral or deleterious for cognitive dysfunction and dementia in these populations.

Exploring the potential implication of NPY in cardiovascular diseases and cognitive dysfunction and dementia by the mendelian randomization approach

Mendelian randomization is an established approach to explore cause–effect relationships minimizing or abolishing confounding in observational settings [79]. This approach needs a genetic single-nucleotide polymorphism (SNP) known

to modify a risk factor suspected to cause a given health outcome. In the specific case of NPY, SNPs that reflect the availability and/or activity of NPY or its receptors can be used as unconfounded predictor variables for cognitive function. Indeed, SNPs are inherited randomly and as such are not subject to confounding by environmental risk factors that may influence the gene product (NPY and NPY receptors in our case). Therefore any link between the SNP and the health outcome of interest should be interpreted as causative. In other words, if an SNP known to increase NPY is also linked to an outcome, high NPY levels must be considered the cause of the outcome. Because some SNPs explored as genetic markers are found only in certain ethnicities and because it is possible that different populations differ for multiple SNPs of diverse genes, mendelian randomization studies demand homogeneous study populations. Mendelian randomization has been used to study genetically regulated variables as possible causes of dementia and telomere length has been associated with Alzheimer's dementia [80].

NPY SNPs. According to the Genome Aggregation database (gnomAD) [81], which comprises three databases (ExAC, gnomAD 2.1 and 3.1) with >80 000 genes, there are 198 NPY variants in the population. Most are too uncommon (from 3 in a million to 9 in 1000) to be used for a mendelian approach. The main SNPs associated with phenotypes of interest for this review are rs16139, rs16147 and rs3037354 (Table 1 and further details shown in Supplementary data, Table S1). The rs16147 (–399C) variant in the promoter region of the NPY gene and the rs2234759 in the Y2R gene [82] associate with faster iconic memory fading in individuals carrying the (rare) G allele of the rs16147 variant and the rs2234759 variant in the Y2R gene, which also associates with increased expression of Y2R.

rs16139 is a benign missense SNP resulting in substitution of leucine by proline at residue 7 in the signal peptide of pre-pro-NPY. It is considered a gain-of-function SNP that modifies the efficiency of NPY processing, facilitating the accumulation of NPY rather than of pro-NPY in endothelial cells and increasing NPY in response to sympathetic stimulation [83]. However, in resting conditions, NPY concentration is lower in L7P subjects than in L7L subjects [84], suggesting that the Leu7Pro polymorphism has different effects on the plasma

NPY kinetics at rest and exercise. It is possible that in resting conditions this polymorphism leads to impaired release and intracellular retention of NPY, followed by an exaggerated release of NPY in high-intensity sympathetic stimulation [84]. The L7P variant has a global frequency of 3%, but its distribution is uneven, ranging from absent in East Asia to 3–4% in South Asia and Europe to 7% in Finland [85]. Thus studies in East Asia will likely be uninformative and inclusion of East Asians in global studies may introduce biases. Information on disease associations of L7P originated in Finland, where >20 years ago it was associated with traits of metabolic syndrome such as weight gain, hyperlipidemia, impaired glucose tolerance, insulin resistance, earlier onset of type 2 diabetes and increased risk of vascular disease [86–90]. It has also been associated with hypertension [91], coronary heart disease [92], diabetic kidney disease [93], diabetic retinopathy [94] and alcohol dependence [95].

rs16147 (–399C) is a 5' UTR SNP, also reported to influence NPY levels, that may potentially interact with L7P. Located in the YNP promoter, it accounted for a 30% decrease in basal gene expression and was a key component of haplotypes associated with lower NPY gene expression [96]. It was associated with higher emotion-induced activation of the amygdala and diminished resiliency as assessed by pain-/stress-induced activations of endogenous opioid neurotransmission in various brain regions [96]. In Finland, five haplotypes were found in 94% of chromosomes. –399C belongs to the frequent H1 haplotype (0.45) and the infrequent H4 haplotype (0.04), both associated with low NPY expression, while the frequency of the H5 haplotype, uniquely containing L7P, was 0.05 and its association with gene expression could not be determined as it was too infrequent in a US sample. In obese males, rs164147 was associated with an increased risk of metabolic syndrome and its related phenotypes, such as central obesity and hyperglycemia [97]. It was also associated with ischemic stroke [98] and early-onset coronary artery disease [99]. In contrast, rs3037354 (∇-880Δ) was associated with increased NPY secretion, enhanced BP response to environmental (cold) stress and higher basal systemic vascular resistance [100] (Supplementary data, Table S1). Finally, rare copy variants and copy number variants have been associated with early-onset obesity [101].

SNPs for NPY receptors. NPY1R, NPY2R and NPY5R are expressed in the brain (Allen Brain Atlas [102] and Human Protein Atlas database [60]). The variants with greater frequency in the population are synonymous variations or variations in the 5' UTR, some of which may influence gene expression and have been associated with phenotypes of interest for kidney, cardiovascular or CNS disease (Supplementary data, Table S1).

Mendelian randomization design for NPY SNPs. Because of its frequency in the general population (3.6% in non-Finnish Europeans) and its repeatedly reported association with outcomes of interest, L7P appears well suited for a mendelian randomization study to disentangle the role of NPY in cognitive impairment in CKD patients. However, such a study should ideally recruit non-Finnish Europeans and/or South Asians to minimize confounding by other genetic

or environmental characteristics found in populations with higher (e.g. Finland) or lower (e.g. East Asia, Africa, American First Nations and descendants) frequencies of the allele. Furthermore, the study should be controlled for common genetic variants in NPY or NPY receptors that have been associated with phenotypes. As alternatives, other NPY SNPs reported to have a functional impact may be used, such as rs16147.

The UK Biobank collected data from >500 000 adults. The cognitive assessment in the UK Biobank is brief and customized and it is administered without supervision, but the test–retest reliability is reasonably good [103]. This biobank provides unparalleled genetic data [104] and represents a unique opportunity for mendelian randomization studies testing the relationship between cognitive function and NPY and YR genes at the general population level and in the CKD population. Furthermore, databases including CKD patients linked with plasma and sera biobanks that collected information on cognitive function exist and these databases may complement genetic databases [105].

Conclusive remarks: why knowledge on the NPY system accumulated so far is still untranslated

In theory, interfering with the NPY system has relevant potential for the treatment of diverse diseases, from CNS diseases to metabolic, cardiovascular and renal diseases. Anxiety, depression, learning and memory and, in general, cognitive problems are all potentially addressable by interventions in the NPY system. However, in the face of a large series of experimental studies in animal models and in genetically engineered animals, until now no pharmacological intervention of the NPY system has been tested in adequately powered clinical studies. The main problem is the complexity of diseases potentially treatable by interfering with the NPY system. The diversity of actions of NPY on organ systems that are in part of opposite sign (e.g. noxious effects in the cardiovascular system and potentially useful effects in the CNS) has probably restrained clinical investigators and the industry to invest in clinical research. Furthermore, because mechanisms underlying energy homeostasis are highly integrated and redundant, interventions on just one component of the system may elicit counter regulatory responses, canceling out the primary effect of the intervention. Furthermore, pharmaceutical formulations for effective drug delivery and cost have been a problem and this explains in part the slow progress of knowledge about the NPY system in the clinical arena. In experimental models, NPY agonists and antagonists have often been administered intracerebrally, which hinders the translation value of findings in these studies to human diseases. Yet YR are expressed in peripheral organs like adipose tissue and the pancreas, indicating a direct function of the NPY system in the control of glucose and energy homeostasis. This suggests that antagonism of peripheral receptors may be useful for the treatment of obesity by routes that can be applied in clinical practice. A recent study [106] tested selective antagonism of peripheral Y1R by BIBO3304, an antagonist that does not pass the blood–brain barrier in diet-induced obesity

in mice. Remarkably, BIBO3304 reduced energy expenditure, body weight and fat mass following exposure to a high-calorie diet. Importantly, Y1R is also expressed in blood vessels, acting as a vasoconstrictor. Therefore peripheral Y1R antagonism has the potential to reduce BP, which has obvious additional benefits. These observations in mice warrant a renewed interest in the NPY system by pharmacologists and clinical investigators alike and will hopefully generate useful application of Y1R antagonism in metabolic and cardiovascular diseases. Cognitive dysfunction and dementia represent the most complex diseases that medicine has to face. With the exception of the NPY trial in post-traumatic depression [35], no human studies have been performed in diseases of the CNS. We are perhaps at a critical juncture in NPY research. New drug formulations and renovated research efforts may propel NPY system research in neurology into a new era. Psychopharmacology developed as a discipline in the mid-20th century. After the discovery of the antidepressants, antipsychotics, anxiolytics and mood stabilizers currently in use today, research slowed down and most major pharmaceutical companies decreased their investment in psychopharmacology. However, new avenues are now being explored [107, 108]. Renewed interest in this area and research on the NPY system may eventually bring the expected benefits for human health by drugs interfering with this system.

SUPPLEMENTARY DATA

Supplementary data are available at [ndt](#) online.

AUTHORS' CONTRIBUTIONS

C.Z. designed the review plan and wrote the first version of the article with F.M., A.O., I.A.B., A.G.B.S., J.M. and G.S. S.R., S.C., and D.V. refined the literature search and integrated the writing of the first version. J.K., V.S., D.R., A.F., M.R., M.C., M.A., G.M., G.T., A.B., B.S., I.R., A.W., M.O. and G.R. critically read the first version of the manuscript and provided suggestions for changes and additions. C.Z. prepared the final version of the article, which was approved by all the authors.

FUNDING

This article is published as part of a supplement financially supported by the COST Action CA19127–Cognitive Decline in Nephro-Neurology: European Cooperative Target (CONNECT).

CONFLICT OF INTEREST STATEMENT

None declared.

APPENDIX

CONNECT collaborators are

Giovambattista Capasso; Alexandre Andrade; Maie Bachmann; Inga Bumblyte; Adrian Constantin Covic; Pilar Delgado; Nicole Endlich; Andreas Engvig; Denis Fouque; Casper Franssen; Sebastian Frische; Liliana Garneata; Loreto Gesu-

aldo; Konstantinos Giannakou; Dimitrios Goumenos; Ayşe Tuğba Kartal; Laila-Yasmin Mani; Hans-Peter Marti; Christopher Mayer; Rikke Nielsen; Vesna Pšić; Merita Rroji (Molla); Giorgos Sakkas; Goce Spasovski; Kate I. Stevens; Evgueni Vazellov; Davide Viggiano; Lefteris Zacharia; Ana Carina Ferreira; Jolanta Malyszko; Ewout Hoorn; Andreja Figurek; Robert Unwin; Carsten A. Wagner; Christoph Wanner; Annette Bruchfeld; Marion Pepin; Andrzej Wiećek; Dorothea Nitsch; Ivo Fridolin; Gaye Hafez; Maria José Soler; Michelangelo Barbieri; Bojan Batinić; Laura Carrasco; Sol Carriazo; Ron Gansevoort; Gianvito Martino; Francesco Mattace Raso; Ionut Nistor; Alberto Ortiz; Giuseppe Paolisso; Daiva Rastenytė; Gabriel Stefan; Gioacchino Tedeschi; Ziad A. Massy; Boris Bikbov; Karl Hans Endlich; Olivier Godefroy; Jean-Marc Chillon; Anastassia Kossioni; Justina Kurganaite; Norberto Perico; Giuseppe Remuzzi; Tomasz Grodzicki; Francesco Trepiccione; Carmine Zoccali; Mustafa Arici; Peter Blankestijn; Kai-Uwe Eckardt; Danilo Fliser; Eugenio Gutiérrez Jiménez; Maximilian König; Ivan Rychlik; Michela Deleidi; George Reusz.

REFERENCES

1. Pedragosa-Badia X, Stichel J, Beck-Sickingler AG. Neuropeptide Y receptors: how to get subtype selectivity. *Front Endocrinol* 2013; 4: 5
2. Shende P, Desai D. Physiological and therapeutic roles of neuropeptide y on biological functions. *Adv Exp Med Biol* 2020; 1237: 37–47
3. Zoccali C. Neuropeptide Y as a far-reaching neuromediator: from energy balance and cardiovascular regulation to central integration of weight and bone mass control mechanisms. Implications for human diseases. *Curr Opin Nephrol Hypertens* 2005; 14: 25–32
4. Tan CMJ, Green P, Tapoulal N *et al.* The role of neuropeptide Y in cardiovascular health and disease. *Front Physiol* 2018; 9: 1281
5. Hubers SA, Wilson JR, Yu C *et al.* DPP (dipeptidyl peptidase)-4 inhibition potentiates the vasoconstrictor response to NPY (neuropeptide Y) in humans during renin-angiotensin-aldosterone system inhibition. *Hypertension* 2018; 72: 712–719
6. You J, Edvinsson L, Bryan RM. Neuropeptide Y-mediated constriction and dilation in rat middle cerebral arteries. *J Cereb Blood Flow Metab* 2001; 21: 77–84
7. Piao FL, Yuan K, Bai GY *et al.* Different regulation of atrial ANP release through neuropeptide Y2 and Y4 receptors. *J Korean Med Sci* 2008; 23: 1027–1032
8. Kringelholz S, Simonsen U, Bek T. Neurogenic contractions in intraocular porcine ciliary arteries are mediated by α 2-adrenoceptors and NPY1 receptors and are inhibited by prostaglandin E2 acting on prejunctional EP4 receptors. *Exp Eye Res* 2013; 107: 32–36
9. Hinson JP. Neuropeptide Y and the regulation of endocrine function. In: Kastin AB (ed.). *Handbook of Biologically Active Peptides* San Diego: Academic Press; 2006: 839–845
10. Chen WC, Liu Y Bin, Liu WF *et al.* Neuropeptide Y Is an immunomodulatory factor: direct and indirect. *Front Immunol* 2020; 11: 580378
11. Farzi A, Reichmann F, Holzer P. The homeostatic role of neuropeptide Y in immune function and its impact on mood and behaviour Europe PMC Funders Group. *Acta Physiol (Oxf)* 2015; 213: 603–627
12. Morris MJ, Cox HS, Lambert GW *et al.* Region-specific neuropeptide Y overflows at rest and during sympathetic activation in humans. *Hypertension* 1997; 29: 137–143
13. Holzer P, Reichmann F, Farzi A. Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis. *Neuropeptides* 2012; 46: 261–274
14. Clarke TB, Davis KM, Lysenko ES *et al.* Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. *Nat Med* 2010; 16: 228–231

15. Murphy KG, Bloom SR. Gut hormones and the regulation of energy homeostasis. *Nature* 2006; 444: 854–859
16. Larsson TA, Tay B-H, Sundström G *et al.* Neuropeptide Y-family peptides and receptors in the elephant shark, *Callorhynchus milii* confirm gene duplications before the gnathostome radiation. *Genomics* 2009; 93: 254–260
17. Larhammar D, Salaneck E. Molecular evolution of NPY receptor subtypes. *Neuropeptides* 2004; 38: 141–151
18. Larhammar D, Wraith A, Berglund MM *et al.* Origins of the many NPY-family receptors in mammals. *Peptides* 2001; 22: 295–307
19. Loetscher M, Geiser T, O'Reilly T *et al.* Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes. *J Biol Chem* 1994; 269: 232–237
20. Caberlotto L, Fuxe K, Sedvall G *et al.* Localization of neuropeptide Y Y1 mRNA in the human brain: abundant expression in cerebral cortex and striatum. *Eur J Neurosci* 1997; 9: 1212–1225
21. Herzog H, Baumgartner M, Vivero C *et al.* Genomic organization, localization, and allelic differences in the gene for the human neuropeptide Y Y1 receptor. *J Biol Chem* 1993; 268: 6703–6707
22. Atlas of Genetics and Cytogenetics in Oncology and Haematology. NPY1R (Neuropeptide Y Receptor Y1) http://atlasgeneticsoncology.org/Genes/GC_NPY1R.html (19 July 2021, date last accessed.)
23. Widdowson PS. Quantitative receptor autoradiography demonstrates a differential distribution of neuropeptide-Y Y1 and Y2 receptor subtypes in human and rat brain. *Brain Res* 1993; 631: 27–38
24. Westfall TC, Chen X, Ciareglio A *et al.* In vitro effects of neuropeptide Y at the vascular neuroeffector junction. *Ann N Y Acad Sci* 1990; 611: 145–155
25. Ammar DA, Eadie DM, Wong DJ *et al.* Characterization of the human type 2 neuropeptide Y receptor gene (NPY2R) and localization to the chromosome 4q region containing the type 1 neuropeptide Y receptor gene. *Genomics* 1996; 38: 392–398
26. Lundell I, Blomqvist AG, Berglund MM *et al.* Cloning of a human receptor of the NPY receptor family with high affinity for pancreatic polypeptide and peptide YY. *J Biol Chem* 1995; 270: 29123–29128
27. Gregor P, Millham ML, Feng Y *et al.* Cloning and characterization of a novel receptor to pancreatic polypeptide, a member of the neuropeptide Y receptor family. *FEBS Lett* 1996; 381: 58–62
28. Schwartz TW. Pancreatic polypeptide: a hormone under vagal control. *Gastroenterology* 1983; 85: 1411–1425
29. Brothers SP, Wahlestedt C. Therapeutic potential of neuropeptide Y (NPY) receptor ligands. *EMBO Mol Med* 2010; 2: 429–439
30. Goldsmith DJA, Covic A, Fouque D *et al.* Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) chronic kidney disease-mineral and bone disorder (CKD-MBD) guidelines: a European Renal Best Practice (ERBP) commentary statement. *Nephrol Dial Transplant* 2010; 25: 3823–3831
31. Gerald C, Walker MW, Criscione L *et al.* A receptor subtype involved in neuropeptide-Y-induced food intake. *Nature* 1996; 382: 168–171
32. Gregor P, Feng Y, DeCarr LB *et al.* Molecular characterization of a second mouse pancreatic polypeptide receptor and its inactivated human homologue. *J Biol Chem* 1996; 271: 27776–27781
33. Weinberg DH, Sirinathsinghji DJS, Tan CP *et al.* Cloning and expression of a novel neuropeptide Y receptor. *J Biol Chem* 1996; 271: 16435–16438
34. Cabrele C, Langer M, Bader R *et al.* The first selective agonist for the neuropeptide YY5 receptor increases food intake in rats. *J Biol Chem* 2000; 275: 36043–36048
35. Sayed S, Van Dam NT, Horn SR *et al.* A randomized dose-ranging study of neuropeptide Y in patients with posttraumatic stress disorder. *Int J Neuropsychopharmacol* 2018; 21: 3–11
36. Ligtenberg G, Blankestijn PJ, Oey PL *et al.* Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. *N Engl J Med* 1999; 340: 1321–1328
37. Grassi G, Biffi A, Seravalle G *et al.* Sympathetic nerve traffic overactivity in chronic kidney disease: a systematic review and meta-analysis. *J Hypertens* 2021; 39: 408–416
38. Grassi G, Seravalle G, Ghiadoni L *et al.* Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease. *Clin J Am Soc Nephrol* 2011; 6: 2620–2627
39. Zoccali C, Mallamaci F, Tripepi G *et al.* Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. *Hypertension* 2002; 40: 41–46
40. Zoccali C, D'Arrigo G, Leonardi D *et al.* Neuropeptide y and chronic kidney disease progression: a cohort study. *Nephrol Dial Transplant* 2018; 33: 1805–1812
41. Lagrauw HM, Westra MM, Bot M *et al.* Vascular neuropeptide Y contributes to atherosclerotic plaque progression and perivascular mast cell activation. *Atherosclerosis* 2014; 235: 196–203
42. Lin S, Boey D, Herzog H. NPY and Y receptors: lessons from transgenic and knockout models. *Neuropeptides* 2004; 38: 189–200
43. Li L, Lee EW, Ji H *et al.* Neuropeptide Y-induced acceleration of postangioplasty occlusion of rat carotid artery. *Arterioscler Thromb Vasc Biol* 2003; 23: 1204–1210
44. Badr EAE, El-Aleem Hassan Abd El-Aleem A, EL-Ghlban S *et al.* Relation of neuropeptide Y gene expression and genotyping with hypertension in chronic kidney disease. *Biochem Biophys Res Commun* 2019; 519: 100666
45. Saraf R, Mahmood F, Amir R *et al.* Neuropeptide Y is an angiogenic factor in cardiovascular regeneration. *Eur J Pharmacol* 2016; 776: 64–70
46. Zoccali C, Mallamaci F, Tripepi G *et al.* Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease. *J Hypertens* 2003; 21: 1355–1362
47. Zoccali C, Mallamaci F, Tripepi G *et al.* Prospective study of neuropeptide Y as an adverse cardiovascular risk factor in end-stage renal disease. *J Am Soc Nephrol* 2003; 14: 2611–7
48. Zoccali C, D'Arrigo G, Leonardi D *et al.* Neuropeptide y predicts cardiovascular events in chronic kidney disease patients: a cohort study. *J Hypertens* 2019; 37: 1359–65
49. Zhang R, Niu H, Kang X *et al.* Long-term administration of neuropeptide Y in the subcutaneous infusion results in cardiac dysfunction and hypertrophy in rats. *Cell Physiol Biochem* 2015; 37: 94–104
50. Chen M, Li X, Dong Q *et al.* Neuropeptide Y induces cardiomyocyte hypertrophy via calcineurin signaling in rats. *Regul Pept* 2005; 125: 9–15
51. Wang J, Hao D, Zeng L *et al.* Neuropeptide Y mediates cardiac hypertrophy through microRNA-216b/FoxO4 signaling pathway. *Int J Med Sci* 2021; 18: 18–28
52. Kanevskij M, Taimor G, Schäfer M *et al.* Neuropeptide Y modifies the hypertrophic response of adult ventricular cardiomyocytes to norepinephrine. *Cardiovasc Res* 2002; 53: 879–887
53. Hung Y-C, Lin C-C, Huang W-L *et al.* Sitagliptin and risk of heart failure hospitalization in patients with type 2 diabetes on dialysis: a population-based cohort study. *Sci Rep* 2016; 6: 30499
54. Remuzzi G. Sympathetic overactivity in hypertensive patients with chronic renal disease. *N Engl J Med* 1999; 340: 1360–1361
55. Kaur J, Young BE, Fadel PJ. Sympathetic overactivity in chronic kidney disease: consequences and mechanisms. *Int J Mol Sci* 2017; 18: 1682
56. Dörr O, Ewen S, Liebetrau C *et al.* Neuropeptide Y as an indicator of successful alterations in sympathetic nervous activity after renal sympathetic denervation. *Clin Res Cardiol* 2015; 104: 1064–1071
57. Puthumana J, Thiessen-Philbrook H, Xu L *et al.* Biomarkers of inflammation and repair in kidney disease progression. *J Clin Invest* 2021; 131: e139927
58. Lay AC, Barrington AF, Hurcombe JA *et al.* A role for NPY-NPY2R signaling in albuminuric kidney disease. *Proc Natl Acad Sci USA* 2020; 117: 15862–15873
59. Hirsch D, Zukowska Z. NPY and stress 30 years later: the peripheral view. *Cell Mol Neurobiol* 2012; 32: 645–659
60. Human Protein Atlas. www.proteinatlas.org (26 November 2021, date last accessed)
61. Yi M, Li H, Wu Z *et al.* A promising therapeutic target for metabolic diseases: neuropeptide Y receptors in humans. *Cell Physiol Biochem* 2018; 45: 88–107
62. Wu Y, He H, Cheng Z *et al.* The role of neuropeptide Y and peptide YY in the development of obesity via gut–brain axis. *Curr Protein Pept Sci* 2019; 20: 750–758
63. Zhang W, Cline MA, Gilbert ER. Hypothalamus-adipose tissue crosstalk: neuropeptide Y and the regulation of energy metabolism. *Nutr Metab* 2014; 11: 1–12

64. Shi Y, Lin S, Castillo L *et al.* Peripheral-specific Y2 receptor knockdown protects mice from high-fat diet-induced obesity. *Obesity* 2011; 19: 2137–2148
65. Morgan CA, Wang S, Southwick SM *et al.* Plasma neuropeptide-Y concentrations in humans exposed to military survival training. *Biol Psychiatry* 2000; 47: 902–909
66. Tural U, Iosifescu DV. Neuropeptide Y in PTSD, MDD, and chronic stress: a systematic review and meta-analysis. *J Neurosci Res* 2020; 98: 950–963
67. Nahvi RJ, Sabban EL. Sex differences in the neuropeptide Y system and implications for stress related disorders. *Biomolecules* 2020; 10: 1248
68. Gray TS, Morley JE. Neuropeptide Y: anatomical distribution and possible function in mammalian nervous system. *Life Sci* 1986; 38: 389–401
69. Göttsche CR, Woldbye DPD. The role of NPY in learning and memory. *Neuropeptides* 2016; 55: 79–89
70. Flood JF, Hernandez EN, Morley JE. Modulation of memory processing by neuropeptide Y. *Brain Res* 1987; 421: 280–290
71. Kornhuber J, Zoicas I. Neuropeptide Y prolongs non-social memory and differentially affects acquisition, consolidation, and retrieval of non-social and social memory in male mice. *Sci Rep* 2017; 7: 6821
72. Minthon L, Edvinsson L, Ekman R *et al.* Neuropeptide levels in Alzheimer's disease and dementia with frontotemporal degeneration. *J Neural Transm Suppl* 1990; 30: 57–67.
73. Minthon L, Edvinsson L, Gustafson L. Somatostatin and neuropeptide y in cerebrospinal fluid: correlations with severity of disease and clinical signs in Alzheimer's disease and frontotemporal dementia. *Dement Geriatr Cogn Disord* 1997; 8: 232–239
74. Duarte-Neves J, Pereira de Almeida L, Cavadas C. Neuropeptide Y (NPY) as a therapeutic target for neurodegenerative diseases. *Neurobiol Dis* 2016; 95: 210–224
75. New York Medical College. Intranasal neuropeptide Y in clinical trial in level two trauma patients for PTSD and acute stress disorder. <https://clinicaltrials.gov/ct2/show/NCT04071600?te> (26 November 2021, date last accessed)
76. Tagay S, Kribben A, Hohenstein A *et al.* Posttraumatic stress disorder in hemodialysis patients. *Am J Kidney Dis* 2007; 50: 594–601
77. Lempert KD, Kopp JB. Renal failure patients in disasters. *Disaster Med Public Health Prep* 2019; 13: 782–790
78. Viggiano D, Wagner CA, Martino G *et al.* Mechanisms of cognitive dysfunction in CKD. *Nat Rev Nephrol* 2020; 16: 452–469
79. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? *Int J Epidemiol* 2003; 32: 1–22
80. Kuźma E, Hannon E, Zhou A *et al.* Which risk factors causally influence dementia? A systematic review of mendelian randomization studies. *J Alzheimers Dis* 2018; 64: 181–193
81. Genome Aggregation Database. <https://gnomad.broadinstitute.org/> (26 November 2021, date last accessed)
82. Arning L, Stock AK, Kloster E *et al.* NPY2-receptor variation modulates iconic memory processes. *Eur Neuropsychopharmacol* 2014; 24: 1298–1302
83. Kallio J, Pesonen U, Kaipio K *et al.* Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans. *FASEB J* 2001; 15: 1242–1244
84. Kallio J, Pesonen U, Jaakkola U *et al.* Changes in diurnal sympathoadrenal balance and pituitary hormone secretion in subjects with Leu7Pro polymorphism in the prepro-neuropeptide Y. *J Clin Endocrinol Metab* 2003; 88: 3278–3283
85. National Center for Biotechnology Information. ClinVar [VCV000000140.1]. <https://www.ncbi.nlm.nih.gov/clinvar/variation/140> (26 November 2021, date last accessed)
86. Karvonen MK, Koulou M, Pesonen U *et al.* Leucine 7 to proline 7 polymorphism in the preproneuropeptide Y is associated with birth weight and serum triglyceride concentration in preschool-aged children 1. *J Clin Endocrinol Metab* 2000; 85: 1455–1460
87. Niskanen L, Karvonen MK, Valve R *et al.* Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with enhanced carotid atherosclerosis in elderly patients with type 2 diabetes and control subjects 1. *J Clin Endocrinol Metab* 2000; 85: 2266–2269.
88. Jaakkola U, Kallio J, Heine RJ *et al.* Neuropeptide Y polymorphism significantly magnifies diabetes and cardiovascular disease risk in obesity: the Hoorn study. *Eur J Clin Nutr* 2009; 63: 150–152
89. Ukkola O, Kesäniemi YA. Leu7Pro polymorphism of preproNPY associated with an increased risk for type II diabetes in middle-aged subjects. *Eur J Clin Nutr* 2007; 61: 1102–1105
90. Karvonen MK, Valkonen V-P, Lakka TA *et al.* Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men. *Atherosclerosis* 2001; 159: 145–151
91. Wallerstedt SM, Skrtic S, Eriksson A-L *et al.* Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive population. *J Hypertens* 2004; 22: 1277–1281
92. Ilveskoski E, Viiri LE, Mikkelsen J *et al.* Neuropeptide Y signal peptide Pro7 substitution protects against coronary artery atherosclerosis: the Helsinki Sudden Death Study. *Atherosclerosis* 2008; 199: 445–450
93. Jaakkola U, Pesonen U, Vainio-Jylhä E *et al.* The Leu7Pro polymorphism of neuropeptide Y is associated with younger age of onset of type 2 diabetes mellitus and increased risk for nephropathy in subjects with diabetic retinopathy. *Exp Clin Endocrinol Diabetes* 2006; 114: 147–152
94. Niskanen L, Voutilainen-Kaunisto R, Teräsvirta M *et al.* Leucine 7 to proline 7 polymorphism in the neuropeptide y gene is associated with retinopathy in type 2 diabetes. *Exp Clin Endocrinol Diabetes* 2000; 108: 235–236
95. Lappalainen J, Kranzler HR, Malison R *et al.* A functional neuropeptide Y Leu7Pro polymorphism associated with alcohol dependence in a large population sample from the United States. *Arch Gen Psychiatry* 2002; 59: 825–831
96. Zhou Z, Zhu G, Hariri AR *et al.* Genetic variation in human NPY expression affects stress response and emotion. *Nature* 2008; 452: 997–1001
97. de Luis DA, Izaola O, de la Fuente B *et al.* Association of neuropeptide Y gene rs16147 polymorphism with cardiovascular risk factors, adipokines, and metabolic syndrome in patients with obesity. *J Nutrigenet Nutrigenomics* 2016; 9: 213–221
98. Fu X-F, Zhang X, Wang D-J *et al.* Neuropeptide Y gene promoter -399T/C polymorphism increases risk of ischemic stroke. *Balkan Med J* 2013; 30: 147–150
99. Shah SH, Freedman NJ, Zhang L *et al.* Neuropeptide Y gene polymorphisms confer risk of early-onset atherosclerosis. *PLoS Genet* 2009; 5: e1000318
100. Zhang K, Rao F, Pablo Miramontes-Gonzalez J *et al.* Neuropeptide Y (NPY): genetic variation in the human promoter alters glucocorticoid signaling, yielding increased NPY secretion and stress responses. *J Am Coll Cardiol* 2012; 60: 1678–1689
101. Serra-Juhé C, Martos-Moreno GÁ, Bou de Pieri F *et al.* Novel genes involved in severe early-onset obesity revealed by rare copy number and sequence variants. *PLoS Genet* 2017; 13: e1006657
102. Allen Institute for Brain Science. Allen Brain Map. <https://portal.brain-map.org> (26 November 2021, date last accessed)
103. Fawns-Ritchie C, Deary IJ. Reliability and validity of the UK Biobank cognitive tests. *PLoS One* 2020; 15: e0231627
104. UK Biobank. Genetic data. <https://www.ukbiobank.ac.uk/enable-your-research/about-our-data/genetic-data> (19 July 2021, date last accessed)
105. Joosten H, Izaks GJ, Slaets JJP *et al.* Association of cognitive function with albuminuria and eGFR in the general population. *Clin J Am Soc Nephrol* 2011; 6: 1400–1409
106. Yulyaningsih E, Zhang L, Herzog H *et al.* NPY receptors as potential targets for anti-obesity drug development. *Br J Pharmacol* 2011; 163: 1170–1202
107. Yan C, Zeng T, Lee K *et al.* Peripheral-specific Y1 receptor antagonism increases thermogenesis and protects against diet-induced obesity. *Nat Commun* 2021; 12: 1–20
108. Robinson E. Psychopharmacology: from serendipitous discoveries to rationale design, but what next? *Brain Neurosci Adv* 2018; 2: 239821281881262.

Received: 30.7.2021; Editorial decision: 13.9.2021